ArticleCurrent issues in molecular biology2026
Candidate miRNA Regulators of Blood Transcriptional Signatures for Differential Diagnosis of Chronic Lymphocytic Leukemia and Multiple Myeloma: A Comprehensive In Silico Study.
Article in Current issues in molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) are biologically distinct hematologic malignancies with heterogeneous clinical courses, and minimally invasive molecular biomarkers are needed to support blood-based discrimination. We performed a comprehensive in silico analysis to derive cross-cohort, direction-consistent transcriptomic programs for CLL and MM and to nominate regulatory microRNAs (miRNAs) linked to these signatures. Public gene-expression datasets from the NCBI Gene Expression Omnibus (two cohorts per disease) were processed with a reproducible workflow to define disease-biased consensus gene sets. Experimentally validated miRNA-target interactions from miRTarBase were integrated with consensus genes for miRNA target over-representation analysis, and miRNA-mRNA networks were constructed to prioritize candidate miRNAs by connectivity. A strict intersection strategy yielded a large, direction-consistent CLL consensus program, whereas a vote-based approach produced a smaller MM program due to a weaker signal in one cohort. Enrichment and network analyses identified compact regulatory modules in CLL, including a highly connected candidate miRNA linked to many CLL-up genes. This framework provides reproducible disease-biased gene programs and evidence-anchored miRNA candidates to support targeted experimental validation and the development of hypothesis-driven blood-based biomarker studies for differential diagnosis and monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.